RecruitingNCT07257796

Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score


Sponsor

Qilu Hospital of Shandong University

Enrollment

3,000 participants

Start Date

Nov 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring. This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Inclusion Criteria2

  • patients aged 40-75 years who undergo the IEE examination
  • patients who voluntarily sign the informed consent form

Exclusion Criteria2

  • patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy
  • patients with previous surgical procedures on the stomach

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTThe diagnostic performance of AI system and endoscopists

Eligible patients will undergo independent EGGIM score assessment by both endoscopists and the AI system.


Locations(3)

Qilu Hospital of Shandong University

Jinan, Shandong, China

Shandong First Medical University First Affiliated Hospital

Jinan, Shandong, China

Shandong Second Provincial General Hospital

Jinan, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07257796


Related Trials